Associated Papers
Low-dose lamotrigine co-administration decreases quetiapine plasma concentrations: Effect of UGT2B7-161C>T polymorphism in Japanese patients with depression.
Suzuki T et al.
International Journal of Clinical Pharmacology and Therapeutics, 2026
UGT polymorphisms and epileptic seizure control in pregnant women treated with Lamotrigine.
Hansen NS et al.
Epilepsy Research, 2025
SNP's use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic.
Moustafa HAM et al.
Functional & Integrative Genomics, 2025
The Loss-of-Function ATP Binding Cassette Subfamily G Member 2 Polymorphism ABCG2 c.421C>A Reduces Lamotrigine Trough Concentrations in Adults with Epilepsy.
Božina N et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2025
The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment.
Wu X et al.
Pharmaceutics, 2024
Impact of UGT1A4 and UGT2B7 polymorphisms on lamotrigine plasma concentration in patients with bipolar disorder.
Zhao T et al.
Pharmacogenetics and Genomics, 2024
The reduced function allele SLCO1B1 c.521T>C is of no practical relevance for the renal graft function over the first post-transplant year in patients treated with mycophenolic acid.
Nađ Škegro S et al.
Pharmacogenetics and Genomics, 2024
Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review.
Belančić A et al.
Croatian Medical Journal, 2024
Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy.
Yang J et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2024
Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy.
Šušak Sporiš I et al.
Fundamental & Clinical Pharmacology, 2024
Distribution pattern of UGT1A6 and UGT2B7 gene polymorphism and its impact on the pharmacokinetics of valproic acid and carbamazepine: Prospective genetic association study conducted in Pakistani patients with epilepsy.
Saleh Faisal M et al.
Gene, 2024
Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma.
Matsumoto J et al.
Molecular and Cellular Biochemistry, 2023
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
Božina N et al.
European Journal of Clinical Pharmacology, 2023
Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study.
Borić-Bilušić AA et al.
Advances in Therapy, 2023
Effects of UGT1A, CYP2C9/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients.
Zheng XX et al.
Pharmacogenomics, 2023
UGT2B7 c.-161C>T polymorphism frequency in Croatian population.
Božina T et al.
Arhiv Za Higijenu Rada I Toksikologiju, 2022
Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab Therapy by PSL.
Li J et al.
Pharmacogenomics and Personalized Medicine, 2022
UGT2B7 gene polymorphism and linkage disequilibrium in pediatric epileptic patients and their influence on sodium valproate monotherapy: A cohort study.
Adiga S et al.
Frontiers in Pharmacology, 2022
Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer.
Joy AA et al.
Clinical Breast Cancer, 2021
UGT1A6 and UGT2B7 Gene Polymorphism and its Effect in Pediatric Epileptic Patients on Sodium Valproate Monotherapy.
Nandith PB et al.
Indian Journal of Pediatrics, 2021
Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.
Božina N et al.
Arhiv Za Higijenu Rada I Toksikologiju, 2021
The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human Diseases.
Jarrar Y et al.
Journal of Personalized Medicine, 2021
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.
Iannaccone T et al.
Pharmaceuticals (basel, Switzerland), 2021
Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies.
Garcia-Rosa S et al.
Current Neuropharmacology, 2021
Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2021
Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients With Epilepsy.
Zhao M et al.
Therapeutic Drug Monitoring, 2020
Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
Kuruc Poje D et al.
Journal of Clinical Pharmacy and Therapeutics, 2020
Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
Božina N et al.
Croatian Medical Journal, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy.
Xu ZY et al.
Frontiers in Pediatrics, 2020
Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration.
Kim SC et al.
Basic & Clinical Pharmacology & Toxicology, 2019
Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy.
Wang ZZ et al.
Frontiers in Pharmacology, 2019
Genetics of perioperative pain management.
Packiasabapathy S et al.
Current Opinion in Anaesthesiology, 2018
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
Vrkić Kirhmajer M et al.
Basic & Clinical Pharmacology & Toxicology, 2018
Clinically Relevant Effect of UGT1A4*3 on Lamotrigine Serum Concentration Is Restricted to Postmenopausal Women-A Study Matching Therapeutic Drug Monitoring and Genotype Data From 534 Patients.
Smith RL et al.
Therapeutic Drug Monitoring, 2018
Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors.
Xu S et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2018
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I et al.
British Journal of Clinical Pharmacology, 2018
Content and Activities of UGT2B7 in Human Liver In Vitro and Predicted In Vivo: A Bottom-Up Approach.
Xu C et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
Association between UDP-glucuronosyltransferase 2B7 tagSNPs and breast cancer risk in Chinese females.
He BX et al.
Clinical and Experimental Pharmacology & Physiology, 2018
Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.
Wang P et al.
European Journal of Clinical Pharmacology, 2018
Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.
Mei S et al.
Seizure, 2017
The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ et al.
Acta Pharmacologica Sinica, 2017
Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.
Fricke-Galindo I et al.
Pharmacogenomics, 2016
Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.
Du Z et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2016
Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.
Milosheska D et al.
British Journal of Clinical Pharmacology, 2016
CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.
Šimić I et al.
Pharmacogenomics, 2016
Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine.
Wang Q et al.
Therapeutic Drug Monitoring, 2016
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Sawyer MB et al.
Clinical Breast Cancer, 2016
Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
Sugishita M et al.
Breast Cancer (tokyo, Japan), 2016
Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.
Liu L et al.
European Journal of Clinical Pharmacology, 2015